<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR11">
 <label>11.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Assouline</surname>
    <given-names>SE</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma</article-title>
  <source>Blood Cancer J</source>
  <year>2014</year>
  <volume>4</volume>
  <fpage>e251</fpage>
  <pub-id pub-id-type="doi">10.1038/bcj.2014.71</pub-id>
  <?supplied-pmid 25325301?>
  <pub-id pub-id-type="pmid">25325301</pub-id>
 </element-citation>
</ref>
